Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
Date:5/10/2013

.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor StatementThis press release contains "forward-looking statements", including statements relating to Lexicon's clinical development of LX4211, telotristat etiprate (LX1032) and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032) and LX1033.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032) and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important fa
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
2. Lexicon to Report First Quarter Financial Results on May 10, 2013
3. Lexicon To Present At The Needham Healthcare Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
5. Lexicon To Present At The BIO CEO & Investor Conference
6. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
8. Lexicon to Provide Third Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
10. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
11. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif., July 30, 2015  Amgen (NASDAQ: ... second quarter of 2015. Key results include: ... second quarter of 2014 to $5,370 million, with ... Enbrel ® (etanercept), Prolia ® (denosumab), ... and XGEVA ® (denosumab). Unfavorable changes in ...
(Date:7/30/2015)... -- Amgen (NASDAQ: AMGN ) today announced the appointment of ... Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the biopharmaceuticals ... , chairman and chief executive officer of Amgen. "Fred,s breadth of ... Mr. Hassan has been Partner and Managing Director ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... announces that a new market research report is ... Triple Analysis: Leukemia, Prostate Cancer and Apoptosis ... This triple analysis focuses on cancer drug development ... by the mechanism/target/effect of Apoptosis. Each of these ...
... SILVER SPRING, Md., May 3, 2011 The U.S. ... Commission (FTC) today announced a joint effort to remove ... treat, cure, and prevent sexually transmitted diseases (STDs). Among ... Viruxo, C-Cure, and Never An Outbreak. (Logo: ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 2Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 3Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 4FDA, FTC Act To Remove Fraudulent STD Products From The Market 2FDA, FTC Act To Remove Fraudulent STD Products From The Market 3
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and the growing number of individuals who remain undiagnosed, treatment options for patients ... shy away from traditional CPAP therapy due to its overall lack of comfort ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on ... by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... drug, biologic and device firms reduce manufacturing errors by 50 percent or more, ...
(Date:7/30/2015)... Ferry, New York (PRWEB) , ... July 31, 2015 , ... ... Barack Obama’s call to action by asking community members to contribute to the College’s ... on, “Helping more of our young people stay on track. Providing the support they ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... and TransCelerate BioPharma, Inc. are pleased to announce that data standards for clinical ... for use on the CDISC website . These three Therapeutic Area (TA) ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5
... Journal of the American Medical Association has published that ... continue their anti-depressant medication to avoid a relapse.// ... University and Massachusetts General Hospital, where 201 pregnant women ... not depressed during the course of the study. According ...
... States has said in its latest report that less than 50 ... dental check-up one a year. This scenario is prevalent even though ... prevented by simple measures. ,AHRQ's Medical Expenditures ... American children did not get dental checkups in 2003. ,* The ...
... Whitaker, parents of Charlie Whitaker, afflicted with a rare ... Human Fertilization and Embryology Authority to consider approval of ... Diamond Blackfan anemia is a rare, potentially fatal // ... transplantation from a sibling with a perfect tissue match ...
... Scottish health department have admitted that blood transfusions may have ... // As many as 3,000 people may have been affected ... of them through the available records. ,Most ... the fact that they have been infected. Furthermore, in most ...
... act as a model for developing better treatment options to ... // Plat, Mayo Clinic is to lead a team of ... million and the research team would be studying the immune ... found that these infants had their thymus removed and though ...
... Diabetes is a big problem and any respite from it ... study on the causes and prevention of diabetes has been ... a first time study as previous ones were done on ... Diabetes and Diabetes Research Centre (a World Health Organisation Collaborating ...
Cached Medicine News:Health News:Pregnancy Not An Antidote To Depression 2Health News:Designer Babies- To Create Or Not To Create! 2Health News:Designer Babies- To Create Or Not To Create! 3Health News:A know how and ready manual for diabetes! 2
... Hoefers Easy Breeze can dry as many as 6 ... (8 x 10 cm) at a time. , ... oven, a specially designed loading platform, and two Hoefer ... awkward connections., The Gel Frame is largely responsible for ...
... dry gels rapidly, evenly and safely, the Hoefer ... and vacuum are applied beneath the gel through ... and agarose gels up to 33 x 44 ... heavy aluminum platen provides even heat distribution and ...
... system, 220-240 V, includes Model 583 gel dryer, ... gel dryer is a vacuum-based gel dryer with ... with variable temperature control and three preprogrammed cycles. ... pump used for pulling vacuum on gel dryers ...
This double-up gel dryer system, 200-240 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
Medicine Products: